Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: Single center experience with 10 cases and review of the literature
- 1 June 2006
- journal article
- review article
- Published by Elsevier in Gynecologic Oncology
- Vol. 101 (3) , 464-469
- https://doi.org/10.1016/j.ygyno.2005.11.010
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- Recurrence of prolactin-producing endometrial stromal sarcoma with sex-cord stromal component treated with progestin and aromatase inhibitorGynecologic Oncology, 2004
- High-grade endometrial stromal sarcoma after treatment with tamoxifen in a patient treated for breast cancerInternational Journal of Gynecologic Cancer, 2003
- Cisplatin-based chemotherapy regimen (DECAV) for uterine sarcomasInternational Journal of Gynecologic Cancer, 2002
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Low-Grade Endometrial Stromal Sarcoma with Cardiovascular Involvement—A Report of Three CasesGynecologic Oncology, 1999
- Tamoxifen and the EndometriumInternational Journal of Gynecological Pathology, 1999
- Low-Grade Endometrial Stromal Sarcoma Preoperative Treatment with Depo-Lupron and MegaceGynecologic Oncology, 1998
- Treatment of Stage IV “High-Grade” Endometrial Stromal Sarcoma with Ifosfamide, Adriamycin, and CisplatinGynecologic Oncology, 1997
- Uterine stromal sarcoma following tamoxifen treatment.Journal of Clinical Pathology, 1995
- Proliferative Stromatosis of the Uterus with Pulmonary MetastasesObstetrics & Gynecology, 1968